参考文献

［1］　Jamal NE，Abi-Saleh B，Ismáeel H.Advances in telemedicine for the management of the elderly cardiac patient［J］.Geriatr Cardiol，2021，18（9）：759-767.

［2］　Vickneson Keeran，Chan Siew-Pang，Li Yue，et al.Coronary artery bypass grafting in patients with low ejection fraction：What are the risk factors？［J］.The Journal of Cardiovascular Surgery：Official Journal of the International Society for Cardiovascular Surgery，2019，60（3）：396-405.

［3］　Piskulic D，McDermott S，Seal L，et al.Virtual visits in cardiovascular disease：A rapid review of the evidence［J］.European journal of Cardiovasc Nurs，2021，20（8）：816-826.

［4］　Silva-Cardoso J，Juanatey JRG，Co min-Colet J，et al.The future of telemedicine in the management of heart failure patients［J］.Card Fail Rev，2021，28（7）：e11.

［5］　Pagliaro BR，Cannata F，Stefanini GG，et al.Myocardial ischemia and coronary disease in heart failure［J］.Heart Fail Rev，2020，25（1）：53-65.

［6］　Rayol SC，SáMPBO，Cavalcanti LRP，et al.Current practice of state-of-the-art coronary revascularization in patients with heart failure［J］.Braz J Cardiovasc Surg，2019，34（1）：93-97.

［7］　Cabral J，Vasconcelos H，Maia-Araújo P，et al.Sacubitril／valsartan in everyday clinical practice：An observational study based on the experience of a heart failure clinic［J］.Cardiovasc Diagn Ther，2021，11（6）：1217-1227.(https://www.daowen.com)

［8］　Brownell NK，Ziaeian B，Fonarow GC.The gap to fill：Rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction［J］.Card Fail Rev，2021，26（7）：e18.

［9］　Cavallari I，Maddaloni E，Nusca A，et al.SGLT-2 inhibitors on top of current pharmacological treatments for heart failure：A comparative review on outcomes and cost effectiveness［J］.Am J Cardiovasc Drugs，2021：17.

［10］　Bright RA，Lima FV，Avila C，et al.Maternal heart failure［J］.J Am Heart Assoc，2021，10（14）：e021019.

［11］　Incze A，KalóZ，Espín J，et al.Assessing the consequences of external reference pricing for global access to medicines and innovation：Economic Analysis and policy implications［J］.Front Pharmacol，2022，13：815029.

［12］　Xue EZ，Zhang MH，Liu CL.Efficacy of ivabradine for heart failure：A protocol for a systematic review of randomized controlled trial［J］.Medicine（Baltimore），2019，98（14）：e15075.

［13］　Zakiyah N，Sinuraya RK，Kusuma ASW，et al.Cost-effectiveness analysis of sacubitril／valsartan compared to enalapril for heart failure Patients in indonesia［J］.Clinicoecon Outcomes Res，2021，13：863-872.